Systemic Bio
Develops 3D bioprinted vascularized organ-on-a-chip models (h-VIOS platform) using hydrogels and human cells for preclinical drug testing, reducing reliance on animal models and accelerating drug discovery timelines.
- CEO / Founder
- Taci Pereira
- Team Size
- 11-50
- Stage
- Defunct
- Total Funding
- $15M
- Latest Round
- Seed
- Key Investors
- 3D Systems
Technology & Products
Key Products
VitalHeal (bioprinted wound patch), h-VIOS™ platform for evaluating the safety of antibody-drug conjugates (ADCs)
Technological Advantage
VERIFIED: Technology derived from 3D Systems' decades of additive manufacturing expertise and acquisition of Allevi, providing high-throughput, reproducible bioprinting capabilities. DEFENSIBLE: Protected by 3D Systems' patent portfolio in additive manufacturing, though specific bioprinting patents not detailed.
Differentiation
Value Proposition
Provides physiologically relevant human tissue models that improve predictive accuracy in drug testing, potentially reducing drug development costs and time-to-market by enabling earlier failure detection and optimization.
How They Differentiate
Offers 10x greater build volume and up to 10x higher resolution than typical bioprinters, enabling production-scale manufacturing of organ models vs. BICO's cost-efficient tools and Organovo's scaffold-free tissues.
Market & Competition
Target Customers
Pharmaceutical and biotechnology companies
Industry Verticals
Pharmaceuticals; Biotechnology; Medical Research
Competitors
Hyku Biosciences
Growth & Milestones
Growth Metrics
Raised $15 million in seed funding; grew to a team of 30; built a 15,000-square-foot facility; could produce 6,000 vascularized hydrogels per month.
Major Milestones
Founded in 2022 with $15M seed funding; Opened 15,000 sq ft state-of-the-art laboratory in Houston in 2023; Won SLAS 2025 Innovation Award; Ceased operations in 2024
Notable Customers
Partnerships with major pharmaceutical firms.